Detalhe da pesquisa
1.
Towards tailored radiopeptide therapy.
Eur J Nucl Med Mol Imaging
; 42(8): 1231-7, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25792454
2.
Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial.
Clin Cancer Res
; 13(22 Pt 1): 6696-702, 2007 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18006770
3.
[Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma.
Clin Cancer Res
; 13(12): 3696-705, 2007 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-17575235
4.
68Ga-labeled bombesin studies in patients with gastrointestinal stromal tumors: comparison with 18F-FDG.
J Nucl Med
; 48(8): 1245-50, 2007 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-17631559
5.
Dosimetry for (90)Y-DOTATOC therapies in patients with neuroendocrine tumors.
Cancer Biother Radiopharm
; 22(1): 130-5, 2007 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-17627421
6.
[Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting.
J Nucl Med
; 47(12): 2025-33, 2006 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-17138746
7.
Candidates for peptide receptor radiotherapy today and in the future.
J Nucl Med
; 46 Suppl 1: 67S-75S, 2005 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-15653654
8.
Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?
J Nucl Med
; 46(9): 1561-9, 2005 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-16157541
9.
CCK-2/gastrin receptor-targeted tumor imaging with (99m)Tc-labeled minigastrin analogs.
J Nucl Med
; 46(10): 1727-36, 2005 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-16204724
10.
GRP receptor-targeted PET of a rat pancreas carcinoma xenograft in nude mice with a 68Ga-labeled bombesin(6-14) analog.
J Nucl Med
; 46(4): 691-9, 2005 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-15809493
11.
Characterization of 68Ga-DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with meningiomas.
J Nucl Med
; 46(5): 763-9, 2005 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-15872348
12.
Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors.
Mol Imaging Biol
; 5(1): 42-8, 2003.
Artigo
em Inglês
| MEDLINE | ID: mdl-14499161
13.
A new peptidic somatostatin agonist with high affinity to all five somatostatin receptors.
Eur J Pharmacol
; 456(1-3): 45-9, 2002 Dec 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-12450568
14.
Analysis of accumulation of 99mTc-octreotide and 99mTc-EDDA/HYNIC-Tyr3-octreotide in the rat kidneys.
Nucl Med Biol
; 31(2): 231-9, 2004 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-15013489
15.
Receptor radionuclide therapy with 90Y-DOTATOC in patients with medullary thyroid carcinomas.
Cancer Biother Radiopharm
; 19(1): 65-71, 2004 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-15068613
16.
Synergism of peptide receptor-targeted Auger electron radiation therapy with anti-angiogenic compounds in a mouse model of neuroendocrine tumors.
EJNMMI Res
; 4(1): 9, 2014 Feb 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-24528513
17.
Targeting GRPR in urological cancers--from basic research to clinical application.
Nat Rev Urol
; 10(4): 235-44, 2013 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-23507930
18.
Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers.
J Clin Oncol
; 30(10): 1100-6, 2012 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22393097
19.
Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers.
J Clin Oncol
; 29(17): 2416-23, 2011 Jun 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-21555692
20.
Agonist-biased signaling at the sst2A receptor: the multi-somatostatin analogs KE108 and SOM230 activate and antagonize distinct signaling pathways.
Mol Endocrinol
; 24(1): 240-9, 2010 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-19910453